Crown disease 19 epidemic
Solidation of Su Yulan
(Washington Composite Electric) Pfizer, a US Pharmaceutical Company, predicts that the crown disease may not end in 2024 and become local epidemics.
Pfizer chief scientific officer Dalsdin issued a report to investors on Friday that Pfizer is expected to continue to appear in some regions in the next one or two years, and other countries will transition to the same period to the same period to the same period to transition to toLocal epidemic, low number of cases and easy to manage.By 2024, crown disease will become local epidemic diseases around the world like flu.
Dorsden said: "How will this happen depends on the evolution of diseases, how the society effectively deploys vaccines and treatment, and distributes the vaccine to the areas with low vaccination rate.The emergence of the new variant virus may also affect the follow -up development of the epidemic. "
Pfizer and Germany Biontech cooperate with the development of coronary vaccines. It is planned to produce 4 billion doses next year. It is expected that this can create $ 31 billion (42.5 billionNew Yuan) income.
Pfizer is estimated to be made after the appearance of Omikon's variants last month.There are more than 50 mutations in this variant strain, which is much more than eight places in Delta, which has led to a decline in the effectiveness of the two doses of Pfizer vaccine to Omikon.The development of the epidemic in various places also shows the speed of the spread of Omikon, faster than other coronary virus strains.
Incorporating a trace vaccine test for young children aged 2 to 4 years old
Pfizer vaccine has been applied to children over 5 years of age in the United States.Pfizer revealed on Friday that the company was also experimented with vaccines with two doses and 3 micrograms of two doses and 3 micrograms of young children 2 to 4 years old. It was found that the immune response generated was not as good as a larger child with higher doses.
However, 3 to 24 months old inoculation of 3 micrograms can still produce similar immune reactions.3 micrograms are one -tenth of the adult dose (30 micrograms), and less than 10 micrograms from 5 to 11 -year -old children.
Pfizer decided to improve clinical trials so that these two groups of children were vaccinated for the third dose after at least two months to test whether the three doses could stimulate stronger immunity.
Pfizer previously expected that this year can get experimental data about children aged 2 to 4 years old. Although the plan is currently lagging behind, Pfizer does not think that this will significantly change it in the second quarter of next year.The crowd applies for emergency use of authorization.
In addition to adult vaccination addition agents, the United States only allows 16 and 17 -year -old adolescents to vaccinate additional agents.
Pfizer also announced on Friday that the 600 -year -old young people from 12 to 17 years have been tested to test the effectiveness of 10 micrograms or 30 micrograms.
Pfizer and Bionech are also developing vaccines for Omikon, and clinical trials are expected to begin in January next year.
